Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
The mitofusin gene (Mfn) encodes two protein molecules, Mfn1 and Mfn2, which play an important role in mitochondrial fusion, division and apoptosis, and regulate the dynamic changes of mitochondrial morphology. In addition, Mfn1/2 is also involved in the energy metabolism of mitochondria and is closely related to the occurrence of related diseases. Mfn1 consists of 742 amino acid residues, localizes to the mitochondrial outer membrane, contains a transmembrane region, and then forms a U-shaped membrane anchor that terminates in the cytoplasm and forms the C-terminus. The C-terminus also has a transmembrane region, and each of the transmembrane regions has a hydrophobic region on each side, similar to a coiled-coil, which plays an important role in triggering mitochondrial fusion.
The Role of Mfn1
Deletion of any of Mfn1 in mice can cause embryonic lethality and mitochondrial fragmentation. Studies have confirmed the crystal structure of Mfn1 in the hydrolysis stage of different GTPases. The structure consists of a GTPase domain and a four-stranded helical bundle (referred to as HD1). Thus, overall Mfn1 has a typical dymamin superfamily member topology.
Mfn1 is involved in embryonic development. Mfn1 knockout mice have embryonic developmental retardation and embryonic death in the second trimester, whereas if the Mfn1 and Mfn2 genes are simultaneously knocked out, mouse embryonic developmental retardation is more pronounced and embryonic death is earlier. Further studies have found that Mfn2 mutant embryonic placenta nourishes giant cell layer cell function is severely impaired, while Mfn1 mutant embryonic placental trophoblast giant cells are normal. In the Mfn1 knockout embryonic fibroblasts, mitochondria are fragmented to varying degrees. An Mfn1 for structural analysis was designed, containing the GTPase (G) domain and the first half of HR1 and the second half of HR2.
Figure 1. Mini-MFN1 and a new proposed model of mitochondrial fusion mediated by MFN1.(Formosa, L E. , et al. 2016)
Mfn1 Fusion with Mitochondria
Studies have shown that the Mfn1 complex plays a role in mitochondrial fusion. Mitochondrial fusion protects cells from apoptosis and acts as a maintenance mechanism for extracellular membrane damage. Studies have shown that a mutation in Mfn1 is highly deleterious in mammalian pregnancy. Mfn1 knockout mice develop severe stunting and tortuosity. If Mfn2 is absent in mouse embryos, the killing effect may be slower, but eventually they will die of placental defects. These studies have shown that cell growth requires mitochondrial fusion, while Mfn1 and Mfn2 are not redundant in this process.
Mfn1 and Mfn2 in mice is beneficial for the protection of mutations in CMT2A type disease caused by mitochondrial fusion defects. Before mitochondria, Mfn1 and Mfn2 form an oligomer-bound mitochondrial outer membrane, and a decrease in Mfn1 or Mfn2 leads to mitochondrial fragmentation. The results of this study show that the mutated Mfn2 forms a complex with Mfn1 or wild-type Mfn2, whereas only the complex containing Mfn1 promotes mitochondrial fusion. In addition, studies have found that patients with dying CMT2A disease may have lower Mfn1/Mfn2 ratios in sensory and motor neurons, and they lack sufficient Mfn1 and Mfn2 to form a complex. Another study found that Mfn1 is a key protein that maintains the tubular structure of the mitochondrial membrane network. When the expression of Mfn1 is decreased, the mitochondria undergo membrane cleavage, and the morphology is broken by the normal tubular membrane network into a small vesicular membrane structure, and the energy synthesis is decreased.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.